PNEUMOCOCCAL DISEASE AND INFLUENZA
Pneumococcal disease is a serious complication of influenza that leads to an estimated 5,000 deaths annually in the US (35). Pneumococcal polysaccharide vaccine (PPSV) coverage rates among New Yorkers aged 65 and older have been persistently below national goals and vary by racial/ethnic groups, with rates of 40% for Asians, 41% for blacks, 48% for Latinos, and 54% for non-Hispanic whites (36).
Recommend pneumococcal vaccine at any time of year for patients who are
- Aged 65 years and older.
- Aged 2 through 64 years with chronic cardiovascular (except hypertension), hepatic, or pulmonary disease (eg, asthma); diabetes; cochlear implants; functional or anatomic asplenia (including those with sickle cell disease).
- Aged 19 through 64 years who smoke cigarettes (11).
- Aged 2 years and older and have compromised immunity, including those with HIV, leukemia, lymphoma, Hodgkin’s disease, multiple myeloma, generalized malignancy, chronic renal failure, and nephritic syndrome; dialysis patients; and people receiving immunosuppressive therapy or organ or bone marrow transplants.
People with functional or anatomic asplenia or any immunocompromising condition will require 1 additional dose of PPSV 5 years after their first dose. Similarly, people who received PPSV before age 65 need to receive 1 additional dose after turning 65 if at least 5 years have elapsed since the previous dose. For full recommendations, see www.cdc.gov/mmwr/preview/mmwrhtml/mm5934a3.htm.
CDC’s Advisory Committee on Immunization Practices recently endorsed vaccination of immunocompromised adults aged 19 years and older with 13-valent pneumococcal conjugate vaccine (PCV-13). Recommendations on using PCV-13 in adults will be available at www.cdc.gov.